Asia Pacific Kidney Disease Market to Grow at a CAGR of 6.9% to reach US$ 37,204.4 Million from 2020 to 2027

The Asia Pacific kidney disease market is expected to reach US$ 37,204.4 million in 2027 from US$ 21,930.1million in 2019. The market is estimated to grow with a CAGR of 6.9% from 2020-2027.

Kidney disease is also known as renal disease. It is caused due to the malfunctioning of the kidney. There are various types of kidney diseases including kidney stones, glomerulonephritis, urinary tract infections, and others. For the treatment and diagnosis of these types of diseases, different global and regional players are offering various products and services. The scope of the kidney disease market includes product, end-user, and region.

China Kidney Disease Market Revenue and Forecasts to 2027 (US$ MN)

Market Insights

Increased Research & Development across the Region

Every country in the Asia Pacific region is now focusing on research and development to boost the healthcare sector. Due to a rise in chronic kidney diseases in the Asia Pacific region, there has been a development in treatment options and hospitalizations. In Australia, by the end of 2014, more than 12,000 Australians were receiving dialysis treatment. This represented a three percent increase in the previous year, and more than 10,000 were living with a functional kidney transplant. The Monash University Diabetes researchers are collaborating with researchers at the South Australian Health and Medical Research Institute (SAHMRI) in South Australia on a project entitled "Reducing the burden of chronic kidney disease in the Indigenous population - the PROPHECY CKD study" (APP1200005), which has been awarded $1,995,895 across five years. Thus, an increase in research and development across the Asia Pacific region in the healthcare sector is likely to create lucrative opportunities for market growth.

Product- Based Market Insights

Based on product,thekidney disease marketis segmented into diagnosis and treatment. The diagnosis segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Asia Pacific Kidney Disease Market, by Product – 2019 and 2027

End-User - Based Market Insights

Based on end-user, the kidney disease market, is segmented into hospitals, diagnostic laboratories, and others. The hospitals segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Asia Pacific Kidney Disease Market: Strategic Insights

Asia Pacific Kidney Disease Market

• 
  CAGR (2020 - 2027)

  6.9%
• Market Size 2019
  US$ 21,930.1 Million
• Market Size 2027
  US$ 37,204.4 Million

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Abbott
• F Hoffmann La Roche Ltd
• AbbVieInc
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc
• Sysmex Corporation
• Siemens AG

Regional Overview

• Asia-Pacific

Market Segmentation

Product

• Diagnosis and Treatment

End User

• Hospitals
• Diagnostic Laboratories

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Product launches and approvals are commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the kidney disease market adopt the expansion, collaboration, and product launch strategies to enlarge customer base across the world. These strategies allow the players to maintain their brand name globally. For instance,In Jan 2020, Sun Pharma has entered into exclusive licensing and supply agreements with Rockwell Medical Inc (Rockwell), to commercialize Rockwell’s Triferic, a proprietary iron replacement and haemoglobin maintenance drug treating anaemia in hemodialysis patients in India.

ASIA PACIFICKIDNEY DISEASE MARKET SEGMENTATION

By Product

• Diagnosis

o      Blood Tests

o      Urine Tests

o      Imaging Tests

o      Others

• Treatment

o      Dialysis

o      Others

o      Drug Class

• • • ACE Inhibitors
    • Angiotensin-II Receptor Blockers
    • Diuretics
    • Others

By End User

• Hospitals
• Diagnostic Laboratories
• Others

By Country

• Asia Pacific

o      Japan

o      China

o      India

o      South Korea

o      Australia

Company Profiles

• Abbott
• F. Hoffmann-La Roche Ltd
• AbbVieInc
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc
• Sysmex Corporation
• Siemens AG

Asia Pacific Kidney Disease Market Report Scope